Plasma sphingolipid profiling , determined by tandem mass spectrometry , was performed in a randomized , double-blind , triple-crossover trial ( n = @ ) of @-week treatment periods with placebo or rosuvastatin ( @ or @ mg/d ) with @-week washouts between treatments .